During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a leading ...
Health and Me on MSN5h
US Doctor Claims Weight Loss Drug, GLP-1, Leads To Suicidal Thoughts And BehaviorsA study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...
Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...
The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.
The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...
Upcoming Investor Conference Skye Bioscience will be a corporate presenter at the 43 rd annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025, at 10:30 AM - 11:10 AM and is available for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback